<SEC-DOCUMENT>0000315066-24-001795.txt : 20240708
<SEC-HEADER>0000315066-24-001795.hdr.sgml : 20240708
<ACCEPTANCE-DATETIME>20240708130700
ACCESSION NUMBER:		0000315066-24-001795
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240708

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neumora Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001885522
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				844367680
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94162
		FILM NUMBER:		241104011

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(857) 760-0900

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RBNC Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210929

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FMR LLC
		CENTRAL INDEX KEY:			0000315066
		STANDARD INDUSTRIAL CLASSIFICATION:	UNKNOWN SIC - 0000 [0000]
		ORGANIZATION NAME:           	
		IRS NUMBER:				043532603
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		245 SUMMER STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		6175706339

	MAIL ADDRESS:	
		STREET 1:		245 SUMMER STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FMR CORP
		DATE OF NAME CHANGE:	19920717
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0000315066</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>COMMON STOCK</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/28/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001885522</issuerCik>
        <issuerName>Neumora Therapeutics, Inc.</issuerName>
        <issuerCusip>640979100</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>490 ARSENAL WAY, SUITE 200</com:street1>
          <com:city>WATERTOWN</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02472</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>FMR LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>8622140.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>8622468.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8622468.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>5.4</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Abigail P. Johnson</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>8622468.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8622468.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>5.4</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Neumora Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>490 ARSENAL WAY, SUITE 200, WATERTOWN, MASSACHUSETTS, 02472.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>FMR LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>245 Summer Street, Boston, Massachusetts 02210</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Not applicable</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>8,622,468</amountBeneficiallyOwned>
        <classPercent>5.405</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Please see the responses to Items 5 and 6 on the cover page</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>8,622,468</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NEUMORA THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of NEUMORA THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>See attached Exhibit 99.</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <exhibitInfo>Please see Exhibit 99 for 13d-1(k) (1) agreement.</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>FMR LLC</reportingPersonName>
      <signatureDetails>
        <signature>Richard Bourgelas</signature>
        <title>Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*</title>
        <date>07/05/2024</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Abigail P. Johnson</reportingPersonName>
      <signatureDetails>
        <signature>Richard Bourgelas</signature>
        <title>Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*</title>
        <date>07/05/2024</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.</signatureComments>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
